Disc Medicine, Inc. Proceeds from Issuance of Convertible Preferred Stock
Disc Medicine, Inc. (IRON) reported Proceeds from Issuance of Convertible Preferred Stock of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2023-03-31
- Disc Medicine, Inc. proceeds from issuance of convertible preferred stock for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Disc Medicine, Inc. proceeds from issuance of convertible preferred stock for fiscal 2021 was $89.86M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-31 |
| 2021-12-31 | $89.86M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |